A PHASE 2, OPEN-LABEL, SINGLE-ARM, COHORT STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF SPARSENTAN TREATMENT IN PEDIATRIC SUBJECTS WITH SELECTED PROTEINURIC GLOMERULAR DISEASES (EPPIK)
Clinical Trial Grant
Administered By
Pediatrics, Nephrology
Awarded By
Travere Therapeutics, Inc
Start Date
November 18, 2021
End Date
February 20, 2025
Administered By
Pediatrics, Nephrology
Awarded By
Travere Therapeutics, Inc
Start Date
November 18, 2021
End Date
February 20, 2025